Articles related to OBESITY/WEIGHT MANAGEMENT

A national analysis found that clinical obesity was present in more than one-quarter of adults with normal BMI values. The findings highlight limitations of BMI alone for identifying excess adiposity and obesity-related health risk.

A phase 2b trial found that biweekly bofanglutide significantly reduced HbA1c levels and produced weight loss in adults with type 2 diabetes. The findings add to ongoing development of longer-interval GLP-1 therapies, though larger and longer studies remain necessary.

Six weeks of moderate sleep restriction increased weight, waist circumference, and sedentary time in adults with baseline adequate sleep and elevated cardiometabolic risk.

The FDA has begun reviewing generic tirzepatide applications as global competition accelerates, despite US patent protections limiting near-term availability.

A 4-week randomized trial in 20 obese men with hypercholesterolemia found that intermittent hypoxic training combined with caloric restriction produced greater reductions in LDL-C, total cholesterol, and triglycerides compared with normoxic training under identical dietary conditions.

The American College of Physicians issued a living clinical guideline recommending semaglutide and tirzepatide as first-line pharmacologic treatments with lifestyle modifications for nonpregnant adults with obesity (BMI 30 kg/m2 or higher) or overweight (BMI 27 to 30 kg/m2) with at least one weight-related comorbidity, with phentermine-topiramate, liraglutide, and naltrexone-bupropion designated as second-, third-, and fourth-line options respectively based on GRADE evidence review.